How to Use Amycretin
Complete guide to Amycretin dosing, administration, timing, and protocol recommendations.
Quick Overview
Amycretin is Novo Nordisk's single-molecule agonist of both the GLP-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. Early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the AMAZE program) in 2026. It is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks.
Dosing Guidelines
Common Dose
Trial doses of 1.25-40 mg once weekly (injection)
Frequency
Once weekly (injection) or once daily (tablet)
Dose Range
0.4-60 mg weekly in trials; 6-100 mg daily for the oral form
Note: These are trial doses, reached by gradual escalation over weeks to months to limit nausea. No dose has been approved, and the oral and injectable forms are not interchangeable mg for mg.
Administration Method
Subcutaneous injection once weekly, or oral tablet once daily (separate formulations)
Best Time to Take
Same day each week (injection); trial protocols set timing for the tablet
The injectable form is long-acting and dosed weekly, so consistency matters more than time of day. Oral peptide tablets usually have strict fasting rules, but amycretin's final label instructions do not exist yet.
Protocol Duration
20-36 weeks in published trials; phase 3 runs longer
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea
- •Vomiting
- •Diarrhea and constipation
- •Reduced appetite
- •GI effects rise with dose and are most common during escalation
Frequently Asked Questions
What is the recommended dose for Amycretin?
Trial doses of 1.25-40 mg once weekly (injection)
How do you administer Amycretin?
Subcutaneous injection once weekly, or oral tablet once daily (separate formulations)
When is the best time to take Amycretin?
Same day each week (injection); trial protocols set timing for the tablet
How long should you use Amycretin?
20-36 weeks in published trials; phase 3 runs longer
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.